L52. Vasculitis treatment: Is it time to change the standard of care for ANCA-associated vasculitis?

Presse Medicale

Volumn 42, Issue 4 PART2, 2013, Pages 643-650

  Hoffman, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HLA DP ANTIGEN; HLA DQ ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; CHURG STRAUSS SYNDROME; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; GENETIC ASSOCIATION; HEALTH CARE QUALITY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LETTER; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

EID: 84875625679     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.047     Document Type: Letter

References (26)

1. Hoffman G.S., Leavitt R.Y., Kerr G.S., Fauci A.S. Treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992, 35:1322-1329.
2. Sneller M.C., Hoffman G.S., Talar-Williams C., Kerr G.S., Hallahan C.E., Fauci A.S. Wegener's granulomatosis: an analysis of 42 patients treated with methotrexate and prednisone. Arthritis Rheum 1995, 38:608-613.
3. de Groot K., Rasmussen N., Bacon P.A., Cohen Tervaert J.W., et al. Randomized trial of cyclophosphamide versus methotrexate in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469.
4. Jayne D., Rasmussen N., Andrassy K., Bacon P., Cohen Tervaert J.W., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
5. Holle J.U., Gross W.L., Latza U., Nolle B., Ambrosch P., Heller M., et al. Improved outcome in 445 patients with Wegener's Granulomatosis in a German Vasculitis Center over four decades. Arthritis Rheum 2011, 63:257-266.
6. Villa-Forte A., Clark T.M., Gomes M., Carey J., Mascha E., Karafa M.T., et al. Substitution of methotrexate for cyclophosphamide in Wegener's granulomatosis. A 12-year single-practice experience. Medicine (Baltimore) 2007, 86(5):269-277.
7. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.-J., Ruivard M., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803.
8. Springer J., Nutter B., Langford C., Hoffman G., Villa-Forte A. Impact of the duration of maintenance therapy on granulomatosis with polyangiitis (Wegener's). ACR 2012, Abstract 1653.
9. Little M.A., Nightingale P., Verburgh C.A., Hauser T., de Groot K., Savage C., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043.
10. Sinico R.A., Di Toma L., Maggiore U., Bottero P., Radice A., Tosoni C., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935.
11. Sable-Fourtassou R., Cohen P., Mahr A., Pagnoux C., Mouthon L., Jayne D., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss Syndrome. Ann Intern Med 2005, 143:632-638.
12. Xiao H., Heeringa P., Hu P., Liu Z., Aratani Y., Maeda N., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
13. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
14. Lyons P.A., Rayner T.F., Trivedi S., Holle J.U., Watts R.A., Jayne D.R.W., et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012, 367:214-223.
15. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
16. Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840.
17. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sanchez-Menendez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 2012, 64:3770-3778.
18. Rhee E.P., Laliberte K.A., Niles J.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody associated vasculitis. Clin J Am Soc Nephrol 2010, 5:1394-1400.
19. Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
20. Guillevin L, Pagnoux C, Karras A, Khoutra C, Aumaitre O, et al. Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ACR 2012. Abstract 1652.
21. Popa C., Leandro M.J., Cambridge G., Edwards J.C.W. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7yrs. Rheumatology (Oxford) 2007, 46:626-630.
22. Keystone E., Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
23. van Vollenhoven R.F., Emery P., Bingham C.O., et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010, 37:558-567.
24. Isvya A., Meuniera M., Gobeaux-Chenevierb C., Maurya E., Wipffa J., Job-Deslandrea C., et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine 2012, 79:365-369.
25. Buch M.H., Smolen J.S., Betteridge N., et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:909-920.
26. Fleischmann R.M. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60:3225-3228.